{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:33:43Z","timestamp":1793226823288,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jmoldx.2026.09.006","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:53:18Z","timestamp":1792597998000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive Genomic Profiling to Improve Access to Targeted Therapies in High-Grade Serous Carcinoma: A Real-World Study (PROMETHEUS)"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1425-3354","authenticated-orcid":false,"given":"Daniele","family":"Lorenzini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Barbetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2078-9988","authenticated-orcid":false,"given":"Alberta","family":"Piccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5808-0387","authenticated-orcid":false,"given":"Adele","family":"Busico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iolanda","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Conca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Bragantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3968-5011","authenticated-orcid":false,"given":"Matteo","family":"Duca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Azzollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Sabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Ardore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalia","family":"Brito da Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1016-4995","authenticated-orcid":false,"given":"Mara","family":"Mantiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Polignano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Ducceschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Ceppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Bogani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tamborini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Buoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vingiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0582-6170","authenticated-orcid":false,"given":"Luca","family":"Agnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Raspagliesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7963-7172","authenticated-orcid":false,"given":"Giancarlo","family":"Pruneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jmoldx.2026.09.006_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.jmoldx.2026.09.006_bib2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive epithelial ovarian cancer survival by histotype and disease stage","volume":"111","author":"Peres","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.jmoldx.2026.09.006_bib3","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA damage response in cancer","volume":"60","author":"O\u2019Connor","year":"2015","journal-title":"Mol Cell"},{"issue":"25","key":"10.1016\/j.jmoldx.2026.09.006_bib4","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jmoldx.2026.09.006_bib5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1136\/ijgc-2023-004786","article-title":"Cost-effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy in the maintenance of patients with homologous recombination deficiency-positive advanced ovarian cancer after response to first-line platinum-based chemotherapy","volume":"34","author":"Cedillo","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"10","key":"10.1016\/j.jmoldx.2026.09.006_bib6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jmoldx.2026.09.006_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.106032","article-title":"ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer","volume":"11","author":"Gonz\u00e1lez-Mart\u00edn","year":"2026","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.jmoldx.2026.09.006_bib8","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1200\/JCO-24-02589","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update","volume":"43","author":"Gaillard","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jmoldx.2026.09.006_bib9","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.jmoldx.2026.09.006_bib10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/14796694.2025.2449782","article-title":"Physician knowledge, use, and perceptions of genetic biomarker testing for the management of patients with newly diagnosed advanced ovarian cancer: an international physician survey","volume":"21","author":"Banerjee","year":"2025","journal-title":"Future Oncol"},{"issue":"12","key":"10.1016\/j.jmoldx.2026.09.006_bib11","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s10147-024-02628-7","article-title":"Real-world application of comprehensive genomic profiling for gynecological malignancies: a multicenter observational study","volume":"29","author":"Fukuda","year":"2024","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jmoldx.2026.09.006_bib12","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.annonc.2025.02.009","article-title":"ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice","volume":"36","author":"Westphalen","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jmoldx.2026.09.006_bib13","article-title":"Molecular tumor board as a clinical tool for converting molecular data into real-world patient care","volume":"7","author":"Vingiani","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jmoldx.2026.09.006_bib14","series-title":"I Numeri del Cancro in Italia 2023","year":"2023"},{"issue":"1","key":"10.1016\/j.jmoldx.2026.09.006_bib15","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1038\/s41598-025-88494-3","article-title":"Detecting gene copy number alterations by Oncomine Comprehensive genomic profiling in a comparative study on FFPE tumor samples","volume":"15","author":"Bozzi","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jmoldx.2026.09.006_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.857515","article-title":"Management of BRCA tumour testing in an integrated molecular tumour board multidisciplinary model","volume":"12","author":"Azzollini","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jmoldx.2026.09.006_bib17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/CCI.19.00132","article-title":"Integrated informatics analysis of cancer-related variants","volume":"4","author":"Pagel","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"issue":"1","key":"10.1016\/j.jmoldx.2026.09.006_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nbt.1754","article-title":"Integrative genomics viewer","volume":"29","author":"Robinson","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.jmoldx.2026.09.006_bib19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"9","key":"10.1016\/j.jmoldx.2026.09.006_bib20","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jmoldx.2026.09.006_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115169","article-title":"Homologous recombination deficiency in ovarian cancer: global expert consensus on testing and a comparison of companion diagnostics","volume":"215","author":"Quesada","year":"2025","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.jmoldx.2026.09.006_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100445","article-title":"Systematic analysis of homologous recombination deficiency testing in ovarian cancer-development of recommendations for optimal assay performance","volume":"37","author":"Romey","year":"2024","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jmoldx.2026.09.006_bib23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ygyno.2023.06.016","article-title":"Palliative care utilization across health sectors for patients with gynecologic malignancies in Ontario, Canada from 2006 to 2018","volume":"175","author":"Mah","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"10106","key":"10.1016\/j.jmoldx.2026.09.006_bib24","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jmoldx.2026.09.006_bib25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13073-024-01413-5","article-title":"Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib","volume":"16","author":"Barnicle","year":"2024","journal-title":"Genome Med"},{"key":"10.1016\/j.jmoldx.2026.09.006_bib26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ygyno.2023.11.027","article-title":"HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma","volume":"180","author":"Koskela","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jmoldx.2026.09.006_bib27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ygyno.2025.02.016","article-title":"Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery","volume":"195","author":"Marchetti","year":"2025","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jmoldx.2026.09.006_bib28","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ygyno.2024.05.024","article-title":"Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1\/2 germline pathogenic variant carriers","volume":"187","author":"Stroot","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"20","key":"10.1016\/j.jmoldx.2026.09.006_bib29","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1158\/1078-0432.CCR-24-1225","article-title":"Effectiveness of PARP inhibitor maintenance therapy in ovarian cancer by BRCA1\/2 and a scar-based HRD signature in real-world practice","volume":"30","author":"Richardson","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jmoldx.2026.09.006_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41698-023-00402-y","article-title":"HRD effects on first-line adjuvant chemotherapy and PARPi maintenance therapy in Chinese ovarian cancer patients","volume":"7","author":"Li","year":"2023","journal-title":"NPJ Precis Oncol"},{"issue":"2","key":"10.1016\/j.jmoldx.2026.09.006_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2024.100054","article-title":"Molecular tumor board for gynecologic malignancies: the real-world experience from the Department for Gynecology and Gynecologic Oncology of Kliniken Essen-Mitte","volume":"35","author":"Tsibulak","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"10.1016\/j.jmoldx.2026.09.006_bib32","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41571-023-00824-4","article-title":"Molecular tumour boards - current and future considerations for precision oncology","volume":"20","author":"Tsimberidou","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.jmoldx.2026.09.006_bib33","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1136\/ijgc-2022-003425","article-title":"A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group","volume":"32","author":"Bartoletti","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.jmoldx.2026.09.006_bib34","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s13046-022-02512-0","article-title":"Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer","volume":"41","author":"Ciliberto","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.jmoldx.2026.09.006_bib35","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.3390\/cancers14235965","article-title":"Homologous recombination deficiency and cyclin E1 amplification are correlated with immune cell infiltration and survival in high-grade serous ovarian cancer","volume":"14","author":"van Wagensveld","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"16_Suppl","key":"10.1016\/j.jmoldx.2026.09.006_bib36","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1200\/JCO.2025.43.16_suppl.5514","article-title":"Safety and preliminary efficacy from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with advanced platinum-resistant and refractory ovarian cancer (OC)","volume":"43","author":"Damian","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jmoldx.2026.09.006_bib37","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/03008916251345409","article-title":"Validating HER2 copy number variation assessment by NGS: a comparative analysis with immunohistochemistry and in situ hybridization","volume":"111","author":"Lorenzini","year":"2025","journal-title":"Tumori"},{"key":"10.1016\/j.jmoldx.2026.09.006_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1633410","article-title":"Genomic instability and CCNE1 amplification as emerging biomarkers for stratifying high-grade serous ovarian cancer","volume":"15","author":"Conca","year":"2025","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.jmoldx.2026.09.006_bib39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.annonc.2022.12.003","article-title":"Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations","volume":"34","author":"Kuzbari","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jmoldx.2026.09.006_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/oncolo\/oyac164","article-title":"Concordance between genomic alterations detected by tumor and germline sequencing: results from a tertiary care academic center molecular tumor board","volume":"28","author":"Green","year":"2023","journal-title":"Oncologist"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157826001832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157826001832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:13:54Z","timestamp":1793225634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157826001832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":40,"alternative-id":["S1525157826001832"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2026.09.006","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive Genomic Profiling to Improve Access to Targeted Therapies in High-Grade Serous Carcinoma: A Real-World Study (PROMETHEUS)","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2026.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}